Atossa Therapeutics (ATOS) closed at $2.72 on October 22, 2026, up 7.5% from the previous close, on volume of 90,562 shares (30-day average 87,571).
Data as of October 22, 2026.
22-Oct-2026
PRNewswire (Mon, 19-Oct 8:01 AM ET)
PRNewswire (Fri, 9-Oct 8:00 AM ET)
PRNewswire (Tue, 29-Sep 8:01 AM ET)
PRNewswire (Thu, 24-Sep 8:01 AM ET)
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
PRNewswire (Fri, 7-Aug 8:45 AM ET)
PRNewswire (Tue, 28-Jul 8:30 AM ET)
Market Chameleon (Mon, 4-May 5:22 AM ET)
FDA Greenlights Atossa’s (Z)-Endoxifen Study, Advancing Hope for Metastatic Breast Cancer Treatment
Market Chameleon (Tue, 6-Jan 6:48 AM ET)
Market Chameleon (Thu, 11-Dec 5:35 AM ET)
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Atossa Therapeutics trades on the NASDAQ stock market under the symbol ATOS.
As of October 22, 2026, ATOS stock price climbed to $2.72 with 90,562 million shares trading.
ATOS has a beta of 1.31, meaning it tends to be more sensitive to market movements. ATOS has a correlation of 0.02 to the broad based SPY ETF.
ATOS has a market cap of $27.13 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ATOS traded as high as $34.65 and as low as $1.70.
The top ETF exchange traded funds that ATOS belongs to (by Net Assets): VTI, VXF, IWC.
ATOS has underperformed the market in the last year with a return of -81.2%, while SPY returned +14.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ATOS shares. However, ATOS has outperformed the market in the last 3 month and 2 week periods, returning +13.3% and +10.6%, while SPY returned +2.3% and -1.7%, respectively. This indicates ATOS has been having a stronger performance recently.
ATOS support price is $2.33 and resistance is $2.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATOS shares will trade within this expected range on the day.
